Claris Biotherapeutics Secures $118 Million in Latest Series B Funding Round

Claris Biotherapeutics secured $118 million in its latest Series B, adding another data point to the Healthcare & Life Sciences funding market.

Claris Biotherapeutics Raises $118 million in Funding

Claris Biotherapeutics Raises $118M in Series B Funding. Image C/O LifeSci Communications Claris Biotherapeutics is setting its sights on a breakthrough in ophthalmology.

Investors Behind the Funding

The round was backed by Samsara BioCapital. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Claris Biotherapeutics operates in Healthcare & Life Sciences. Claris Biotherapeutics's financing adds to recent private-market activity.

Strategic Use of Funds

Advance its eye drug into pivotal trials.

Looking Ahead

Claris Biotherapeutics Raises $118M in Series B Funding

Source reference: original announcement/article.